Loading organizations...

§ Private Profile · Tampere, Finland
StemSight is a technology company.
StemSight is a Finnish high-tech startup developing off-the-shelf cell therapies for corneal blindness. The company leverages human pluripotent stem cells to create advanced treatments specifically targeting unmet medical needs in ocular conditions such as Limbal Stem Cell Deficiency. Their technical approach focuses on accelerating tissue regeneration, enhancing the safety profile of cell therapies, and streamlining the delivery mechanisms for these complex treatments.
The company was founded in 2021 by Heli Skottman and Laura Koivusalo, with Ms. Koivusalo serving as CEO. Their insight stemmed from extensive research in stem cell biology, recognizing the potential to translate laboratory advancements into practical, sight-restoring therapies. The founders aimed to bridge the gap between cutting-edge scientific discovery and clinical application for patients suffering from severe eye conditions.
StemSight targets patients experiencing severe corneal blindness who can benefit from regenerative medicine. The company’s long-term vision is to cure blindness with stem cells, aspiring to bring innovative induced pluripotent stem cell treatments to a broader patient population. They are dedicated to delivering effective, sight-restoring therapies and achieving "Vision Unlimited" for individuals globally.
StemSight has raised $3.3M across 2 funding rounds.
StemSight has raised $3.3M in total across 2 funding rounds.
StemSight has raised $3.3M in total across 2 funding rounds.
StemSight's investors include Voima Ventures.
StemSight has raised $3.3M across 2 funding rounds. Most recently, it raised $2.7M Other Equity in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 13, 2025 | $2.7M Venture Round | Voima Ventures | — | Announced |
| Sep 1, 2021 | $590K Seed | — | Voima Ventures | Announced |
StemSight is a Finnish biotech startup developing off‑the‑shelf, iPS‑cell–derived corneal cell therapies to restore vision in patients with corneal blindness, initially targeting limbal stem cell deficiency (LSCD). [1][5]
High‑Level Overview
For a portfolio company (StemSight itself):
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: StemSight is a focused, academically rooted European deep‑tech startup translating iPS‑cell and biomaterials science into a potentially curative, off‑the‑shelf corneal therapy; its near‑term value rests on de‑risking preclinical to clinical translation and proving manufacturability at scale, after which it could materially change treatment options for corneal blindness [5][2][4].
If you’d like, I can: